Global Oncology Based In-Vivo CRO Market to Reach US$ 1.8 Billion by 2028, Strengthened by Rising Incidences of Cancer

February 24, 2023 | Healthcare

The latest report by IMARC Group, titled “Oncology Based In-Vivo CRO Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028,” finds that the global oncology based in-vivo CRO market size reached US$ 1.1 Billion in 2022. Oncology refers to the study of diagnosis, prevention, and treatment of cancer. It relies on a range of techniques, including biopsy, endoscopy, X-ray, computed tomography (CT) scanning, magnetic resonance imaging (MRI), positron emission tomography (PET) scanning, and ultrasound. It provides immunotherapy, radiotherapy, hormonal therapy, and oral therapies to patients for enduring and relieving the side effects of cancer. Oncology-based in-vivo CRO involves cancer management with the help of contract research organization (CRO) services. Since it offers preclinical drug development, testing, and infection diagnosis research in the field of oncology, oncology-based in-vivo CRO is gaining immense traction across the globe. 


Global Oncology Based In-Vivo CRO Market Trends:

The rising incidences of cancer among the masses represent the primary factor driving the market growth. Moreover, the higher economic efficiency and expertise in cancer treatment offered by CROs compared to an in-house study has led to a substantial shift toward outsourcing research and development (R&D) activities by major pharmaceutical companies. Along with this, the growing focus on the oncogene study to regulate cell proliferation, growth, and differentiation has augmented the demand for oncology-based in-vivo CRO. Additionally, there has been a surge in the use of telehealth and virtual clinical trials in the healthcare sector to ensure the safety of cancer patients. In line with this, ongoing advancements in genetic engineering for manipulating deoxyribonucleic acid (DNA) and modifying the characteristics of organisms has propelled the market growth. Furthermore, the rising funding from government organizations for R&D activities and the surging need to reduce the overall trial expenditure is positively influencing the market growth. Besides this, the rapid growth of generics and biosimilars, coupled with the increasing competition among pharmaceutical manufacturers due to upcoming patent expirations, has accelerated product adoption rates. Other factors, including the development of several investigational compounds by CROs for treating cancer, widespread availability of medicines, the aging population, and improvements in the healthcare infrastructure, are also creating a favorable market outlook. Looking forward, IMARC Group expects the market value to reach US$ 1.8 Billion by 2028, growing at a CAGR of 7.65% during 2023-2028. 


Market Summary:

  • The market has been classified based on the indication into blood cancer, solid tumors, and others. Currently, solid tumors represent the largest market segment.
  • Based on the model, the market has been segmented into syngeneic, xenograft, patient derived xenograft (PDX), and others. Amongst these, patient derived xenograft (PDX) exhibits a clear dominance in the market.
  • On the basis of the application, the market has been bifurcated into hospitals and rehabilitation centers.
  • Region-wise, North America (the United States and Canada) holds the leading position in the market. Other major regions include Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa. 
  • The competitive landscape of the market has also been examined, with some of the key players being Champions Oncology Inc., Charles River Laboratories International Inc., Crown Bioscience Inc., Eurofins Scientific, Evotec SE, ICON Plc, Labcorp Drug Development (Laboratory Corporation of America Holdings), Living Tumor Laboratory, Taconic Biosciences Inc., The Jackson Laboratory, WuXi AppTec, and Xentech.

Report Scope:

Report Features Details
Base Year of the Analysis 2022
Historical Period 2017-2022
Forecast Period 2023-2028
Units US$ Billion
Segment Coverage Indication, Model, Application, Region
Region Covered  Asia Pacific, Europe, North America, Latin America, Middle East and Africa
Countries Covered United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
Companies Covered Champions Oncology Inc., Charles River Laboratories International Inc., Crown Bioscience Inc., Eurofins Scientific, Evotec SE, ICON Plc, Labcorp Drug Development (Laboratory Corporation of America Holdings), Living Tumor Laboratory, Taconic Biosciences Inc., The Jackson Laboratory, WuXi AppTec and Xentech
Customization Scope 10% Free Customization
Report Price and Purchase Option Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
Post-Sale Analyst Support 10-12 Weeks
Delivery Format PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)


About Us:

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

Contact Us:

IMARC Group
30 N A
Email: Sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Global Oncology Based In-Vivo CRO Market to Reach US$ 1.8 Billion by 2028, Strengthened by Rising Incidences of Cancer
Purchase options Year End sale



Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More